Intech Investment Management LLC Cuts Holdings in Boston Scientific Corporation $BSX

Intech Investment Management LLC lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 45.6% in the 4th quarter, Holdings Channel reports. The firm owned 176,245 shares of the medical equipment provider’s stock after selling 147,689 shares during the period. Intech Investment Management LLC’s holdings in Boston Scientific were worth $16,805,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Murphy & Mullick Capital Management Corp increased its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. United Community Bank increased its holdings in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the last quarter. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $49.12 on Friday. The firm has a market cap of $73.01 billion, a price-to-earnings ratio of 20.55, a P/E/G ratio of 0.93 and a beta of 0.62. The firm has a fifty day moving average price of $60.69 and a 200 day moving average price of $78.84. Boston Scientific Corporation has a fifty-two week low of $48.41 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BSX shares. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. UBS Group lowered their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Finally, Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $87.46.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.